Comparative Preclinical Evaluation of Three Recombinant Brucella Vaccine Formulations, BruVac-Pro, BruVac-CPX and BruVac-FLU, in a Murine Brucella melitensis Challenge Model
Background/Objectives: Brucellosis remains a widespread zoonosis, yet no licensed human vaccine exists and the live attenuated vaccines used in animals are unsuitable for people because of residual virulence and the risk of accidental infection. Recombinant platforms are attractive alternatives, but direct head-to-head...